<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9769">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05690646</url>
  </required_header>
  <id_info>
    <org_study_id>NCRC2023001</org_study_id>
    <nct_id>NCT05690646</nct_id>
  </id_info>
  <brief_title>Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery</brief_title>
  <acronym>PEP</acronym>
  <official_title>Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery During COVID-19 Pandemics: A Prospective, Randomized Controlled, Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prophylactic effect of nirmatrelvir/ritonavir and ursodeoxycholic acid on reducing&#xD;
      complications after cardiac surgery during covid-19 pandemics (the pep trial) is a&#xD;
      multicenter, randomized controlled trial. The aim of the pep trial is to investigate whether&#xD;
      prophylactic use of nirmatrelvir/ritonavir and ursodeoxycholic could reduce complications&#xD;
      after cardiac surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After informed consent, four centers and 436 eligible admissions will be recruited. Eligible&#xD;
      patients would be randomized (1:1:1:1) to nirmatrelvir/ritonavir group (nirmatrelvir 300mg&#xD;
      q12h and ritonavir 100 mg q12h for 5 days), ursodeoxycholic acid group (ursodeoxycholic acid&#xD;
      group, 15mg/kg/day bid for5 days), combination group (nirmatrelvir/ritonavir and&#xD;
      ursodeoxycholic acid for 5days) and control group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 28, 2023</start_date>
  <completion_date type="Anticipated">January 6, 2026</completion_date>
  <primary_completion_date type="Actual">March 24, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACCE</measure>
    <time_frame>30 days after surgery or during hospitalization</time_frame>
    <description>All-cause mortality, myocardial infarction, stroke, moderate to severe acute kidney injury, and COVID-19 pneumonia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days after surgery or during hospitalization</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Myocardial infarction</measure>
    <time_frame>30 days after surgery or during hospitalization</time_frame>
    <description>new onset of myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Stroke</measure>
    <time_frame>30 days after surgery or during hospitalization</time_frame>
    <description>new onset of stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Moderate to severe acute kidney injury</measure>
    <time_frame>30 days after surgery or during hospitalization</time_frame>
    <description>new onset of moderate to severe acute kidney injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of COVID-19 pneumonia</measure>
    <time_frame>30 days after surgery or during hospitalization</time_frame>
    <description>new onset of COVID-19 pneumonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Cardiogenic death</measure>
    <time_frame>30 days after surgery or during hospitalization</time_frame>
    <description>Cardiogenic death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Severe pneumonia</measure>
    <time_frame>30 days after surgery or during hospitalization</time_frame>
    <description>new onset of Severe pneumonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Ventilation ≥24h</measure>
    <time_frame>30 days after surgery or during hospitalization</time_frame>
    <description>Ventilation ≥24h after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Pulmonary embolism</measure>
    <time_frame>30 days after surgery or during hospitalization</time_frame>
    <description>new onset of Pulmonary embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Re-operation for bleeding</measure>
    <time_frame>30 days after surgery or during hospitalization</time_frame>
    <description>Re-operation for bleeding after primary surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>1 year after surgery</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Myocardial infarction</measure>
    <time_frame>1 year after surgery</time_frame>
    <description>new onset of Myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Stroke</measure>
    <time_frame>1 year after surgery</time_frame>
    <description>new onset of Stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Renal insufficiency</measure>
    <time_frame>1 year after surgery</time_frame>
    <description>new onset of Renal insufficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Re-hospitalization for respiratory disease</measure>
    <time_frame>1 year after surgery</time_frame>
    <description>Re-hospitalization for respiratory disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Cardiogenic re-hospitalization</measure>
    <time_frame>1 year after surgery</time_frame>
    <description>Cardiogenic re-hospitalization</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">491</enrollment>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>NR group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nirmatrelvir 300mg q12h and ritonavir 100 mg q12h for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ursodeoxycholic acid group, 15mg/kg/day bid for5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combination group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nirmatrelvir 300mg q12h and ritonavir 100 mg q12h for 5 days and ursodeoxycholic acid group, 15mg/kg/day bid for5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nirmatrelvir/ritonavir</intervention_name>
    <description>nirmatrelvir 300mg q12h and ritonavir 100 mg q12h for 5 days</description>
    <arm_group_label>NR group</arm_group_label>
    <arm_group_label>combination group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic acid</intervention_name>
    <description>ursodeoxycholic acid 15mg/kg/day bid for5 days</description>
    <arm_group_label>UA group</arm_group_label>
    <arm_group_label>combination group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  COVID-19 nucleic acid test or antigen test positive history, without symptom or&#xD;
             recover from COVID-19 related symptoms ≥2 weeks&#xD;
&#xD;
          -  Receive open-chest cardiac surgery&#xD;
&#xD;
          -  COVID-19 nucleic acid test and antigen test negative and no signs of pneumonia in&#xD;
             chest CT&#xD;
&#xD;
          -  Patients with written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  eGFR ≤30ml/min&#xD;
&#xD;
          -  Severe liver dysfunction&#xD;
&#xD;
          -  Contraindication to nirmatrelvir/ritonavir or ursodeoxycholic acid&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shengshou Hu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>10010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 9, 2023</study_first_submitted>
  <study_first_submitted_qc>January 18, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2023</study_first_posted>
  <last_update_submitted>April 7, 2023</last_update_submitted>
  <last_update_submitted_qc>April 7, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Nirmatrelvir</mesh_term>
    <mesh_term>Nirmatrelvir and ritonavir drug combination</mesh_term>
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

